iCell Gene Therapeutics

Biotechnology ResearchNew York, United States11-50 Employees

iCell Gene Therapeutics is a clinical-stage biopharmaceutical company in the biotechnology research sector, based at 25 Health Sciences Drive, Stony Brook, New York. The company develops chimeric antigen receptor (CAR) immunotherapies, including CARvac, T-cell targeted CARs, compound CARs, and non-gene edited universal CARs. Its clinical programs target autoimmune disorders, acute myeloid leukemia (AML), and T-cell malignancies, with trials conducted in the United States and China. The organization reports 11-50 employees and has revenue in the range of $10 million to $25 million. Historical notes include an October 2018 exclusive North American licensing and research services agreement for an anti-CD19 CAR T therapy with LinearxDNA/LineaRx, and a September 2021 publication of a clinical study on cCAR T-cell immunotherapy for lupus.

Sign up for free to view info

Email Format Employee directory